xaluritamig   Click here for help

GtoPdb Ligand ID: 13718

Synonyms: AMG 509 | AMG-509 | AMG509
Compound class: Antibody
Comment: Xaluritamig (AMG 509) is a humanised bispecific monoclonal antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1; on prostate tumour cells) and CD3e (on T cells) [2]. It is a bispecific T cell engager (BiTE) class monoclonal, that was designed for therapeutic use against prostate cancer. Engaging these two surface molecules facilitates immune mediated killing of STEAP1-expressing cancer cells. Cryo-electron microscopy reveals that the anti-STEAP1 Fab domain of xaluritamig binds to a STEAP1 homotrimer.
Click here for help
References
1. Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB et al.. (2024)
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Cancer Discov, 14 (1): 76-89. [PMID:37861461]
2. Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM et al.. (2024)
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Cancer Discov, 14 (1): 90-103. [PMID:37861452]